Dacarbazine
Other Alkylating Agents
- Drug class
- Other Alkylating Agents
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 8
- FDA reports (12 mo)
- 438
Overview
Dacarbazine is an active pharmaceutical ingredient in the Other Alkylating Agents group (L01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | February 20, 2026 |
| US United States | FDA | 1 | September 22, 2025 |
| CA Canada | Health Canada | 3 | April 16, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Dacarbazine is indicated for the treatment of patients with metastasised malignant melanoma. Further indications for dacarbazine as part of a combination chemotherapy are: • advanced Hodgkin’s disease, • advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma).
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Dacarbazine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL115870008 · revised February 13, 2026
- [2]FDA DailyMed · 0d81315c-7021-40… · revised September 22, 2025 [PDF]
- [3]Health Canada (DPD) · 02241445 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.